Table 5 Immune checkpoint inhibitors, Treatment response in NSCLC
Total | ATB | no ATB | p value | Total | ATB | no ATB | p value | ||
|---|---|---|---|---|---|---|---|---|---|
CR | 0 | 0 | 0 | 0.006 | OR | 29 (24%) | 8 (16%) | 21 (30%) | 0.085 |
PR | 29 (24%) | 8 (16%) | 21 (30%) | nOR | 92 (76%) | 42 (84%) | 50 (70%) | ||
SD | 51 (42%) | 17 (34%) | 34 (48%) | DC | 80 (66%) | 25 (50%) | 55 (78%) | 0.002 | |
PD | 41 (34%) | 25 (50%) | 16 (22%) | nDC | 41 (34%) | 25 (50%) | 16 (22%) | ||
Total | 121 | 50 | 71 | Total | 121 | 50 | 71 |